menu
    • menu
    [{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"AMP-100","moa":"Na channel","graph1":"Ophthalmology","graph2":"Phase III","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SINTETICA SA \/ Harrow","highestDevelopmentStatusID":"10","companyTruncated":"SINTETICA SA \/ Harrow"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Cross Research S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Chloroprocaine","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase III","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"SINTETICA SA \/ Cross Research S.A.","highestDevelopmentStatusID":"10","companyTruncated":"SINTETICA SA \/ Cross Research S.A."},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Chloroprocaine","moa":"Sodium channel alpha subunit","graph1":"Ophthalmology","graph2":"Phase III","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SINTETICA SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SINTETICA SA \/ Undisclosed"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SINTETICA SA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SINTETICA SA \/ Undisclosed"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Drops","sponsorNew":"SINTETICA SA \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SINTETICA SA \/ Undisclosed"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"SINTETICA SA \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SINTETICA SA \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by SINTETICA SA

    Menu

    SINTETICA SA

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SINTETICA SA

                            Switzerland arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SINTETICA SA

                            Switzerland arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chloroprocaine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Cross Research S.A.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Chloroprocaine 3% Gel and Oxybuprocaine 0.4% Eye Drops Anesthesia in Pediatric Populati...

                            Details : Chloroprocaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 03, 2023

                            Lead Product(s) : Chloroprocaine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Cross Research S.A.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SINTETICA SA

                            Switzerland arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SINTETICA SA

                            Switzerland arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sintetica US Launches Lidocaine Hydrochloride Injection, USP 1%, 2% and 4%

                            Details : Lidocaine hydrochloride is a local anesthetic used in a wide variety of superficial and invasive procedures, it works by blocking sodium channels and thus decreasing the rate of contractions of the heart.

                            Product Name : Lidocaine Hydrochloride-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 27, 2023

                            Lead Product(s) : Lidocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SINTETICA SA

                            Switzerland arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SINTETICA SA

                            Switzerland arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMP-100

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Harrow

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica

                            Details : AMP-100 is a patented, innovative ocular surface anesthetic drug candidate, with safety and efficacy supported by a recently completed Phase 3 study that successfully compared the efficacy and tolerability of AMP-100 to current standards of care.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 27, 2021

                            Lead Product(s) : AMP-100

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Harrow

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SINTETICA SA

                            Switzerland arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SINTETICA SA

                            Switzerland arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety and Local Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers

                            Details : This drug candidate is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 03, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SINTETICA SA

                            Switzerland arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SINTETICA SA

                            Switzerland arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers

                            Details : This drug candidate is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 15, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SINTETICA SA

                            Switzerland arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SINTETICA SA

                            Switzerland arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chloroprocaine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.

                            Details : Chloroprocaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cataract.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 28, 2020

                            Lead Product(s) : Chloroprocaine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth